AAX Biotech welcomes new CEO

28 September 2023
boardroom_big

Sweden-based AAX Biotech revealed that Maria Lisa Knudsen has been appointed as chief executive of the company. Dr Knudsen has a broad international experience in research and business development.

Having obtained a PhD in infection biology from the Karolinska Institutet, she conducted extensive research at renowned institutions in the USA and Singapore. Subsequently, she made a transition to the role of business development director at Salipro Biotech in Sweden, where Dr Knudsen was involved in out-licensing the company’s technology platform for drug discovery as well as establishing an internal pipeline.

“We are thrilled to have Maria join the team as we strengthen our IP portfolio and build partnerships with biotech and pharma companies. Maria’s combined experience in antibody research and business development will be instrumental for advancing AAX Biotech’s cutting-edge technologies for antibody therapeutics,” says Daniel Johansson, co-founder and chief scientific officer of AAX Biotech.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology